DNA synthesis upstart raises $10M to scale operations

Ca­me­na Bio­science, a UK biotech, raised $10 mil­lion as it works on im­prov­ing the ac­cu­ra­cy of DNA syn­the­sis.

The Se­ries A, led by UK ven­ture cap­i­tal fund Mer­cia As­set Man­age­ment, will go to­ward con­tin­u­ing de­vel­op­ment of the biotech’s DNA syn­the­sis plat­form, and it will al­so be used to hire 10 more em­ploy­ees, the biotech an­nounced Mon­day. The com­pa­ny cur­rent­ly em­ploys 15 peo­ple.

Ca­me­na CEO and co-founder Steve Har­vey told End­points News that the com­pa­ny, which was found­ed in 2016, be­gan mak­ing rev­enue last year af­ter sign­ing com­mer­cial deals with “lead­ing con­sumers of syn­thet­ic genes,” ac­cord­ing to a re­lease.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN